Latest News Releases

PBAC APPROVES XIFAXAN® (RIFAXAMIN α) 550 mg COST EFFECTIVENESS IN AUSTRALIA

Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the use of XIFAXAN 550 mg in the prevention of the recurrence of hepatic encephalopathy where other treatments have failed More...

view all news releases

As a leading European specialty pharmaceutical company, Norgine develops, manufactures and markets innovative medicines for the benefit of patients, employees and all other stakeholders

Corporate Web Site